Endocrinology, Vol 135, 2240-2247, Copyright © 1994 by Endocrine Society

ARTICLES

Expression of transforming growth factor-beta 1 in prostate cancer

MS Steiner, ZZ Zhou, DC Tonb and ER Barrack
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Transforming growth factor-beta 1 (TGF beta 1) is a potent modulator of cell proliferation, differentiation, angiogenesis, and the immune system. TGF beta 1 messenger RNA (mRNA) levels were much higher in several rat prostate adenocarcinomas (Dunning R3327 MATLyLu, AT2, G, HI, and H sublines) than in normal prostate. Normal prostate and the well differentiated H and HI tumors produced two TGF beta 1 mRNA transcripts, 2.4 kilobases (major) and 1.6 kilobases (minor). The poorly differentiated MATLyLu and AT2 sublines produced these plus additional TGF beta 1 mRNA transcripts that were present in the primary tumors, metastases, and cultured cell lines. TGF beta 1 mRNA levels were unchanged 2 weeks after castration. Immunohistochemical staining of TGF beta 1 protein was more prominent and more extensive in prostate cancer than in normal prostate. Only extracellular TGF beta 1 staining was detected. In normal prostate and in well differentiated tumors (H and HI), extracellular TGF beta 1 staining was located in the interacinar stroma, suggesting that it may be produced there. In contrast, in the poorly differentiated tumors (MATLyLu, AT2, and G) that contain sheets of epithelial cells, extracellular TGF beta 1 staining was present throughout the tumor, suggesting that TGF beta 1 may be made and secreted by the tumor epithelial cells. MATLyLu, AT2, and G tumor cells were cultured in vitro, and the conditioned medium was analyzed for the presence of TGF beta using a bioassay. TGF beta 1 is produced and secreted as an inactive latent precursor and must be activated to release bioactive TGF beta 1. Cells secreted about 100-500 pg TGF beta/10(6) cells.24 h and were able to activate about 50% of the total TGF beta secreted. Because TGF beta 1 mRNA and protein expression are higher in cancerous than normal tissue and because prostate cancer cells themselves can activate latent TGF beta 1 to a bioactive form, TGF beta 1 produced endogenously by prostate cancer has the potential to affect tumor behavior in vivo. Therefore, TGF beta 1 may represent a new therapeutic target in prostate cancer.

This article has been cited by other articles:

				S. Shankar, S. Ganapathy, and R. K. Srivastava Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis Clin. Cancer Res., November 1, 2008; 14(21): 6855 - 6866. [Abstract] [Full Text] [PDF]

				B. A Teicher, J. M Yingling, and J. M McPherson TGF{beta} Blockade as Anticancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 71 - 81. [Abstract] [Full Text] [PDF]

				B. A. Teicher Transforming Growth Factor-{beta} and the Immune Response to Malignant Disease Clin. Cancer Res., November 1, 2007; 13(21): 6247 - 6251. [Abstract] [Full Text] [PDF]

				S. Lu, J. Lee, M. Revelo, X. Wang, S. Lu, and Z. Dong Smad3 Is Overexpressed in Advanced Human Prostate Cancer and Necessary for Progressive Growth of Prostate Cancer Cells in Nude Mice Clin. Cancer Res., October 1, 2007; 13(19): 5692 - 5702. [Abstract] [Full Text] [PDF]

				M. C Fleisch, C. A Maxwell, and M.-H. Barcellos-Hoff The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocr. Relat. Cancer, June 1, 2006; 13(2): 379 - 400. [Abstract] [Full Text] [PDF]

				F. Zhang, J. Lee, S. Lu, C. A. Pettaway, and Z. Dong Blockade of Transforming Growth Factor-{beta} Signaling Suppresses Progression of Androgen-Independent Human Prostate Cancer in Nude Mice Clin. Cancer Res., June 15, 2005; 11(12): 4512 - 4520. [Abstract] [Full Text] [PDF]

				M. K. O'Bryan, O. Gerdprasert, D. J. Nikolic-Paterson, A. Meinhardt, J. A. Muir, L. M. Foulds, D. J. Phillips, D. M. de Kretser, and M. P. Hedger Cytokine profiles in the testes of rats treated with lipopolysaccharide reveal localized suppression of inflammatory responses Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1744 - R1755. [Abstract] [Full Text] [PDF]

				M. J. Morris and H. I. Scher Clinical Approaches to Osseous Metastases in Prostate Cancer Oncologist, April 1, 2003; 8(2): 161 - 173. [Abstract] [Full Text] [PDF]

				F. Zhang, W. Lu, and Z. Dong Tumor-infiltrating Macrophages Are Involved in Suppressing Growth and Metastasis of Human Prostate Cancer Cells by INF-{beta} Gene Therapy in Nude Mice Clin. Cancer Res., September 1, 2002; 8(9): 2942 - 2951. [Abstract] [Full Text] [PDF]

				A. J. Sakko, C. Ricciardelli, K. Mayne, W. D. Tilley, R. G. LeBaron, and D. J. Horsfall Versican Accumulation in Human Prostatic Fibroblast Cultures Is Enhanced by Prostate Cancer Cell-derived Transforming Growth Factor {beta}1 Cancer Res., February 1, 2000; 61(3): 926 - 930. [Abstract] [Full Text]

				R. M. Adam, J. G. Borer, B. J. Williams, J. A. Eastham, K. R. Loughlin, and M. R. Freeman Amphiregulin Is Coordinately Expressed with Heparin-Binding Epidermal Growth Factor-Like Growth Factor in the Interstitial Smooth Muscle of the Human Prostate Endocrinology, December 1, 1999; 140(12): 5866 - 5875. [Abstract] [Full Text]

				B. Loras, F. Vetele, A. E. Malki, J. Rollet, J.-C. Soufir, and M. Benahmed Seminal transforming growth factor-ß in normal and infertile men Hum. Reprod., June 1, 1999; 14(6): 1534 - 1539. [Abstract] [Full Text] [PDF]

				P. J. Kaplan, S. Mohan, P. Cohen, B. A. Foster, and N. M. Greenberg The Insulin-like Growth Factor Axis and Prostate Cancer: Lessons from the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Model Cancer Res., May 1, 1999; 59(9): 2203 - 2209. [Abstract] [Full Text] [PDF]

				M. J. Gerdes, T. D. Dang, M. Larsen, and D. R. Rowley Transforming Growth Factor-{beta}1 Induces Nuclear to Cytoplasmic Distribution of Androgen Receptor and Inhibits Androgen Response in Prostate Smooth Muscle Cells Endocrinology, August 1, 1998; 139(8): 3569 - 3577. [Abstract] [Full Text] [PDF]

				M. J. Gerdes, M. Larsen, L. McBride, T. D. Dang, B. Lu, and D. R. Rowley Localization of Transforming Growth Factor-b1 and Type II Receptor in Developing Normal Human Prostate and Carcinoma Tissues J. Histochem. Cytochem., March 1, 1998; 46(3): 379 - 388. [Abstract] [Full Text]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]

				N.-S. Chang Hyaluronidase enhancement of TNF-mediated cell death is reversed by TGF-beta 1 Am J Physiol Cell Physiol, December 1, 1997; 273(6): C1987 - C1994. [Abstract] [Full Text] [PDF]

				L. Sun and C. Chen Expression of Transforming Growth Factor beta  Type III Receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells J. Biol. Chem., October 3, 1997; 272(40): 25367 - 25372. [Abstract] [Full Text] [PDF]